TY - JOUR
T1 - Whole-body magnetic resonance imaging (WB-MRI) in oncology
T2 - recommendations and key uses
AU - On behalf of the Italian Working Group on Magnetic Resonance
AU - Petralia, Giuseppe
AU - Padhani, Anwar R.
AU - Pricolo, Paola
AU - Zugni, Fabio
AU - Martinetti, Marco
AU - Summers, Paul E.
AU - Grazioli, Luigi
AU - Colagrande, Stefano
AU - Giovagnoni, Andrea
AU - Bellomi, Massimo
PY - 2019/3/13
Y1 - 2019/3/13
N2 - The past decade has witnessed a growing role and increasing use of whole-body magnetic resonance imaging (WB-MRI). Driving these successes are developments in both hardware and software that have reduced overall examination times and significantly improved MR imaging quality. In addition, radiologists and clinicians have continued to find promising new applications of this innovative imaging technique that brings together morphologic and functional characterization of tissues. In oncology, the role of WB-MRI has expanded to the point of being recommended in international guidelines for the assessment of several cancer histotypes (multiple myeloma, melanoma, prostate cancer) and cancer-prone syndromes (Li–Fraumeni and hereditary paraganglioma–pheochromocytoma syndromes). The literature shows growing use of WB-MRI for the staging and follow-up of other cancer histotypes and cancer-related syndromes (including breast cancer, lymphoma, neurofibromatosis, and von Hippel–Lindau syndromes). The main aim of this review is to examine the current scientific evidence for the use of WB-MRI in oncology.
AB - The past decade has witnessed a growing role and increasing use of whole-body magnetic resonance imaging (WB-MRI). Driving these successes are developments in both hardware and software that have reduced overall examination times and significantly improved MR imaging quality. In addition, radiologists and clinicians have continued to find promising new applications of this innovative imaging technique that brings together morphologic and functional characterization of tissues. In oncology, the role of WB-MRI has expanded to the point of being recommended in international guidelines for the assessment of several cancer histotypes (multiple myeloma, melanoma, prostate cancer) and cancer-prone syndromes (Li–Fraumeni and hereditary paraganglioma–pheochromocytoma syndromes). The literature shows growing use of WB-MRI for the staging and follow-up of other cancer histotypes and cancer-related syndromes (including breast cancer, lymphoma, neurofibromatosis, and von Hippel–Lindau syndromes). The main aim of this review is to examine the current scientific evidence for the use of WB-MRI in oncology.
KW - Cancer screening
KW - Cancer-related syndromes
KW - Diffusion-weighted imaging
KW - Magnetic resonance imaging
KW - Oncology
KW - Whole-body MRI
UR - http://www.scopus.com/inward/record.url?scp=85056706014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056706014&partnerID=8YFLogxK
U2 - 10.1007/s11547-018-0955-7
DO - 10.1007/s11547-018-0955-7
M3 - Review article
C2 - 30430385
AN - SCOPUS:85056706014
VL - 124
SP - 218
EP - 233
JO - Radiologia Medica
JF - Radiologia Medica
SN - 0033-8362
IS - 3
ER -